Over at In the Pipeline, Derek Lowe's reaction to a new McKinsey report on pharma's return on investment elicits this succinct response: "Yikes." According to the report, ROI from small-molecule drug research has dropped from 12 percent in the late '90s to about 7.5 percent this decade.